OncoZenge investor relations material
Listen to the latest call from OncoZenge
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. Its products include Palonosetron Fertiginject, an antiemetic product developed and launched in the Nordics; and Yserenate, a pharmaceutical preparation that is used for the treatment of hyperammonemia in patients with N-acetylglutamate synthase deficiency, as well as for the treatment of hypophosphatemia in patients with chronic kidney disease. The company was founded in 2020 and is headquartered in Bromma, Sweden.
Ticker
ONCOZCountry
SEAbout
IR-page